RKRebecca Portney Kirby

Rebecca Portney Kirby

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rebecca Portney Kirby has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Global stakeholder preferences for point-of-care HIV nucleic acid amplification tests: A conjoint study

    by Kara M. Palamountain, Chethana Achar, Rebecca P. Kirby, Yukari C. Manabe, Debi Boeras, Michal Maimaran

    Introduction: This study aimed to assess global stakeholder preferences for key attributes of point-of-care (POC) HIV Nucleic Acid Amplification Tests (NAAT), with the aim of informing product development to support progress toward UNAIDS 95-95-95 targets. Methods: A web-based conjoint survey was conducted in August through November 2024 among HIV clinicians, laboratory professionals, and researchers. Participants were asked to evaluate hypothetical POC HIV NAAT profiles varying by six attributes: sensitivity / limit of detection (LOD), sample-collection method, turnaround time (TAT), result format, price, and power source. Relative importance and part-worth utilities were calculated to assess trade-offs in decision-making. Results: One hundred three respondents from 33 countries, primarily in Africa (75%), completed the survey. The relative importance placed on the attributes in the conjoint task varied based on the setting. In community and home-based settings, participants prioritized fingerstick sample collection (25.90%) and faster TATs (28.8%), even at the expense of sensitivity (15.70%). By contrast, respondents from hospitals and health centers valued tests with high sensitivity (42.6%, 40.9%) and faster TATs (31.5%, 22.6%). Across all respondents, price (7.0%), result format (3.30%), and power source (7.25%) were less influential. Conclusions: Stakeholders were willing to make trade-offs among desirable attributes, prioritizing rapid turnaround time, strong sensitivity, and fingerstick sampling over affordability, power requirements, and result format in the conjoint task. These preferences vary by level of care and by use case, underscoring the importance of aligning product features with contextual needs. Engaging stakeholders early in the design process is critical to ensure new POC HIV NAAT technologies are both acceptable and scalable in low-resource settings.

  • Open Access

    Aligning neonatal sepsis triage diagnostics with WHO target product profiles in low- and middle-income countries

    by Birgitta Gleeson, Benjamin Blumel, Ana Belen Ibarz Pavon, Rebecca P Kirby, Cannon Hansen, Berra Erkosar, Naomi E Spotswood, Yasir Bin Nisar, Kara M Palamountain

    Neonatal sepsis is a leading cause of infant morbidity and mortality in low- and middle-income countries (LMICs), yet despite this, progress in the development and implementation of effective diagnostics has been limited. Current diagnostic methods rely on clinical assessments of nonspecific signs and symptoms, limited laboratory testing and technologies that are inaccessible, unaffordable or unsuitable for resource-constrained settings. There is an urgent need for reliable, affordable and context-appropriate point-of-care diagnostics. This analysis synthesises evidence across current and emerging diagnostic strategies for neonatal sepsis, including clinical algorithms, host-response biomarkers, haematological parameters, continuous monitoring and artificial intelligence-based digital platforms. We assess their performance, operational feasibility in LMICs and alignment with the WHO Target Product Profile (TPP) for neonatal sepsis, including requirements for highly sensitive triage, feasibility in non-hospital settings and suitability for use at the point of care in LMICs. We identified promising existing technologies and emerging approaches that could be used to address the challenges of diagnosing neonatal sepsis in LMICs. These include host-response biomarkers that offer greater accuracy than those currently used, as well as affordable technologies that can improve current predictive algorithms. Taken together, these findings support a move towards integrated, TPP-aligned diagnostic strategies that combine affordable point-of-care testing, routine clinical data and digital decision support to improve early detection, rationalise antibiotic use and reduce neonatal mortality.


  • The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States

    by Yukari C Manabe, Matthew M Hamill, Kara M Palamountain, Chad J Achenbach, Kevin P Delaney, Yu-Hsiang Hsieh, Joyce L Jones, Rebecca P Kirby, Sally M McFall, William O Osburn, et al.

    In global settings, both the clinical use case and value proposition have been well articulated. This has led to the development of many point-of-care (POC) diagnostics for infectious diseases. However, in the United States, more than 80% of infectious disease diagnostics are performed in reference laboratories that have high throughput but relatively long turnaround times. As the cost of POC assays has decreased with nucleic acid test (NAT) innovation catalyzed by the coronavirus disease 2019 pandemic, we sought to develop clinical use cases for human immunodeficiency virus (HIV) NATs and the technical specifications that would tip the value proposition toward commercialization and meaningful adoption. Without POC HIV NATs, we are unlikely to achieve our collective goal of HIV elimination in the United States.


  • Open Access

    From warehouse to ward: applying implementation research methods to the device identification, qualification, distribution, and management process within the Newborn Essential Solutions and Technologies (NEST360) alliance

    by Kylie Dougherty, Rebecca P. Kirby, Katerina Claud, Kara M. Palamountain, Elizabeth Asma, Millicent Alooh, Danica Kumara, Vince Gate, Ali Khalid, George Banda, et al.

    Preventing newborn deaths requires the right medical devices. However, in many countries, devices for small and sick newborn care (SSNC) are unavailable, not fit for the environment, or broken. Newborn Essential Solutions and Technologies (NEST360) is a multicountry alliance aimed at decreasing neonatal mortality in Kenya, Malawi, Nigeria, and Tanzania. The technology qualification, distribution, and management teams in NEST360 work to ensure appropriate devices are available and functional at facilities, by identifying needed technologies, sourcing suitable devices, testing them under varied conditions, establishing reliable supply chains, training staff, and maintaining the devices once installed through trained biomedical technicians. We applied implementation research (IR) to understand context, describe strategy selection, and implementation outcomes of the work designed to ensure the consistent availability of functional SSNC devices. Between March and July 2024, we conducted 12 in-depth interviews with NEST360 team members via Zoom, and reviewed quantitative programmatic data, including device functionality reports. We applied deductive content analysis for interviews and descriptive statistics for quantitative data. Results were used to develop an implementation research logic model (IRLM) using NEST360 and United Nations Children’s Fund SSNC Implementation Toolkit for contextual factors and the Reach Effectiveness Adoption Implementation Maintenance (RE-AIM) framework for implementation outcomes. We identified 40 contextual factors, 78% being barriers. Twenty-one strategies were implemented to address barriers to device qualification, distribution, and management efforts, including engaging stakeholders and conducting ongoing trainings. Notable implementation outcomes included reach with 29 devices in 12 product categories qualified, and all 66 facilities received NEST-qualified devices, effectiveness, in 2024, an average of 87% of all newborn care devices were functional, including those provided by NEST360 and those sourced through existing channels, adoption with over 2476 devices installed at NEST360 sites in 2023. Acceptability was also high with country-level biomedical technicians reporting positive facility-level experiences using the devices. The NEST360 approach to ensuring appropriate and functioning equipment for SSNC was successful through multiple strategies to address multilevel barriers. The use of IR facilitated understanding of how strategies addressed context and where change is needed. These results will be used in plans for scale-up and dissemination.


  • Open Access

    From warehouse to ward: Applying implementation research methods to the device identification, qualification, distribution, and management process within the NEST360 alliance

    by Kylie Dougherty, Rebecca P. Kirby, Katerina Claud, Kara M. Palamountain, Elizabeth Asma, Millicent Alooh, Danica Kumara, Vince Gate, Nicki Bisceglia, Ali Khalid, et al.

    Background: Preventing newborn deaths is possible with the right medical devices. However, in many countries, devices for small and sick newborn care (SSNC) are either unavailable, not fit for the environment, or broken. Newborn Essential Solutions and Technologies (NEST360) is a multicountry interdisciplinary alliance aimed at decreasing neonatal mortality in Kenya, Malawi, Nigeria, and Tanzania. The technology qualification, distribution and management teams in NEST360 work to ensure appropriate devices are available and functional at facilities. Their work involves identifying which technologies are needed, sourcing devices that fit those needs, testing those devices’ functional ability under varied conditions, establishing a reliable supply chain, training facility staff in use, and maintaining the devices once installed through trained biomedical technicians. We applied implementation research (IR) to understand context, describe strategy selection, and implementation outcomes of the work designed to ensure the consistent availability of functional devices for SSNC. Methods: Between March and July 2024, we conducted in-depth interviews with NEST360 team members via Zoom, and reviewed quantitative programmatic data, including device functionality reports. We applied deductive content analysis for interviews and descriptive statistics for quantitative data. Results were used to develop an implementation research logic model (IRLM) using NEST360 and UNICEF’s SSNC Implementation Toolkit for contextual factors and RE-AIM for implementation outcomes. Results: We identified 40 contextual factors, 78% being barriers. Twenty-one strategies were implemented to address barriers to device qualification, distribution, and management efforts, including engaging stakeholders and conducting ongoing trainings. Notable implementation outcomes included Reach with 29 devices in 12 product categories qualified, and all 66 facilities received NEST-qualified devices , Effectiveness , in 2024, an average of 87% of all newborn care devices were functional, including those provided by NEST360 and those sourced through existing channels, Adoption with over 2,476 devices installed at NEST360 sites in 2023 . Acceptability was also high with country-level biomedical technicians reporting positive facility-level experiences using the devices. Conclusions: NEST360 approach to ensuring appropriate and functioning equipment for SSNC was successful through multiple strategies to address multilevel barriers. The use of IR facilitated understanding of how strategies addressed context and where change is needed. These results will be used in plans for scale-up and dissemination. Contributions to the literature: This study utilizes implementation research (IR) methodologies to examine the contextual factors, strategies, and outcomes of maintaining functional medical devices for small and sick newborn care (SSNC) in four countries. By developing an implementation research logic model (IRLM), this study provides a structured approach to understanding how device access and sustainability can be improved in resource-limited settings. The study identified 40 contextual factors in multiple areas and levels influencing the availability of functional devices, including human resource constraints, governance issues, financial barriers, and infrastructure challenges. It maps these barriers and facilitators to 21 targeted strategies that align with the Expert Recommendations for Implementation Research (ERIC) framework, providing a blueprint for overcoming diverse challenges. The study explores long-term sustainability of the NEST360-supported work by identifying key areas for improvement, such as financing for spare parts, strengthening preventive maintenance practices, and advocating for policy reforms.

  • Open Access

    A call to bridge the diagnostic gap: diagnostic solutions for neonatal sepsis in low- and middle-income countries

    by Birgitta Gleeson, Cecilia Ferreyra, Kara Palamountain, Shevin T Jacob, Naomi Spotswood, Niranjan Kissoon, Yasir Bin Nisar, Felicity Fitzgerald, Sarah Murless-Collins, Uduak Okomo, et al.


  • Open Access

    Target product profiles for neonatal care devices: systematic development and outcomes with NEST360 and UNICEF

    by Rebecca P. Kirby, Elizabeth M. Molyneux, Queen Dube, Cindy McWhorter, Beverly D. Bradley, Martha Gartley, Z. Maria Oden, Rebecca Richards-Kortum, Jennifer Werdenberg-Hall, Danica Kumara, et al.

    Background: Medical devices are critical to providing high-quality, hospital-based newborn care, yet many of these devices are unavailable in low- and middle-income countries (LMIC) and are not designed to be suitable for these settings. Target Product Profiles (TPPs) are often utilised at an early stage in the medical device development process to enable user-defined performance characteristics for a given setting. TPPs can also be applied to assess the profile and match of existing devices for a given context. Methods: We developed initial TPPs for 15 newborn product categories for LMIC settings. A Delphi-like process was used to develop the TPPs. Respondents completed an online survey where they scored their level of agreement with each of the proposed performance characteristics for each of the 15 devices. Characteristics with < 75% agreement between respondents were discussed and voted on using Mentimeter™ at an in-person consensus meeting. Findings: The TPP online survey was sent to 180 people, of which 103 responded (57%). The majority of respondents were implementers/clinicians (51%, 53/103), with 50% (52/103) from LMIC. Across the 15 TPPs, 403 (60%) of the 668 performance characteristics did not achieve > 75% agreement. Areas of disagreement were voted on by 69 participants at an in-person consensus meeting, with consensus achieved for 648 (97%) performance characteristics. Only 20 (3%) performance characteristics did not achieve consensus, most (15/20) relating to quality management systems. UNICEF published the 15 TPPs in April 2020, accompanied by a report detailing the online survey results and consensus meeting discussion, which has been viewed 7,039 times (as of January 2023). Conclusions: These 15 TPPs can inform developers and enable implementers to select neonatal care products for LMIC. Over 2,400 medical devices and diagnostics meeting these TPPs have been installed in 65 hospitals in Nigeria, Tanzania, Kenya, and Malawi through the NEST360 Alliance. Twenty-three medical devices identified and qualified by NEST360 meet nearly all performance characteristics across 11 of the 15 TPPs. Eight of the 23 qualified medical devices are available in the UNICEF Supply Catalogue. Some developers have adjusted their technologies to meet these TPPs. There is potential to adapt the TPP process beyond newborn care.


  • Open Access

    Improved screening of retinopathy of prematurity (ROP): development of a target product profile (TPP) for resource-limited settings

    by Rebecca P Kirby, Aeesha N J Malik, Kara M Palamountain, Clare E Gilbert

    Background As more preterm infants survive, complications of preterm birth, including retinopathy of prematurity (ROP), become more prevalent. ROP rates and blindness from ROP are higher in low-income and middle-income countries, where exposure to risk factors can be higher and where detection and treatment of ROP are under-resourced or non-existent. Access to low-cost imaging devices would improve remote screening capabilities for ROP. Methods Target product profiles (TPPs) are developed early in the medical device development process to define the setting, target user and range of product requirements. A Delphi-like process, consisting of an online survey and consensus meeting, was used to develop a TPP for an ROP imaging device, collecting feedback on a proposed set of 64 product requirements. Results Thirty-six stakeholders from 17 countries provided feedback: clinicians (72%), product developers (14%), technicians (6%) and other (8%). Thirty-six per cent reported not currently screening for ROP, with cited barriers including cost (44%), no training (17%) and poor image quality (16%). Among those screening (n=23), 48% use more than one device, with the most common being an indirect ophthalmoscope (87%), followed by RetCam (26%) and smartphone with image capture (26%). Consensus was reached on 53 (83%) product requirements. The 11 remaining were discussed at the consensus meeting, and all but two achieved consensus. Conclusions This TPP process was novel in that it successfully brought together diverse stakeholders to reach consensus on the product requirements for an ROP imaging devices. The resulting TPP provides a framework from which innovators can develop prototypes.


  • Open Access

    Is there a “price that’s right” for at-home COVID tests?

    by Rebecca Portney Kirby, Michal Maimaran, Kara M Palamountain

    The COVID-19 pandemic has impacted the daily lives of individuals across the world as multiple variants continue introducing new complexities. In December 2021, which is when we conducted our study, pressure to resume the normalcy of daily life was mounting as a new variant, Omicron, was rapidly spreading. A variety of at-home tests detecting SARS-CoV-2, known to the general public as “COVID tests,” were available for consumers to purchase. In this study, we conducted conjoint analysis utilizing an internet-based survey by presenting consumers (n = 583) with 12 different hypothetical at-home COVID test concepts that varied on five attributes (price, accuracy, time, where-to-buy, and method). Price was identified as the most important attribute, because participants were very price sensitive. Quick turnaround time and high accuracy were also identified as important. Additionally, although 64% of respondents were willing to take an at-home COVID test, only 22% reported they had previously taken the test. On December 21, 2021, President Biden announced the U.S. government would purchase 500 million at-home rapid tests and distribute them for free to Americans. Given the importance of price to participants, this policy of providing free at-home COVID tests was directionally appropriate.